Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Dermatology | Oncology | Family Medicine
Melanoma Clinical Trials
A listing of Melanoma medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Birmingham : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Birmingham : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Arizona
Scottsdale : Mayo Clinic Arizona - Cancer Clinical Research Unit
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Scottsdale : Oncology Research Associates, Pllc D/B/A
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Scottsdale : TGen Clinical Research Service at Scottsdale Healthcare
Safety Study of PLX108-01 in Patients With Solid Tumors
Scottsdale : Call for Information (Investigational Site 0004) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Scottsdale : Pinnacle Oncology Hematology Updated
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
View More »
Tucson : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Tucson : Arizona Clinical Research
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Tucson : University of Arizona Cancer Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Tucson : Call for Information (Investigational Site 0007) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Tucson :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Arkansas
Fayetteville : Highlands Oncology Group Dept of Highlands Oncology Grp
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Little Rock : University of Arkansas for Medical Sciences
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
California
Beverly Hills : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Beverly Hills : Beverly Hills Cancer Center
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Beverly Hills : Call for Information (Investigational Site 0061) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Duarte : City of Hope
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Encinitas : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
View More »
Encinitas : San Diego Pacific Oncology and Hematology Associates, Inc.
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
La Jolla : Moores UCSD Cancer Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
La Jolla : Moores UCSD Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
La Jolla :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Los Angeles :
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma
Los Angeles : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Los Angeles :
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Los Angeles :
A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Los Angeles : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Los Angeles : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Los Angeles :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Los Angeles :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Los Angeles : The Angeles Clinic & Research Institute
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy
Los Angeles : University of California Los Angeles
Combination of Temozolomide and Sunitinib in Treatment of Patients With Metastatic and Unresectable Malignant Melanoma
Los Angeles : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Los Angeles : Childrens Hospital Of La
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Los Angeles : USC Norris Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Los Angeles : University of California, Los Angeles
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Los Angeles : UCLA
Safety Study of PLX108-01 in Patients With Solid Tumors
Los Angeles : The Angeles Clinic and Research Institute
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Los Angeles : The Angeles Clinic and Research Institute
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Los Angeles : Call for Information (Investigational Site 0010) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Los Angeles : Call for Information (Investigational Site 0015) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Los Angeles : Call for Information (Investigational Site 0034) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Los Angeles : Call for Information (Investigational Site 0018) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Los Angeles :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Los Angeles : Cedars Sinai Medical Center Updated
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Orange : Children'S Hospital Of Orange County
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Orange : Chao Family Comprehensive Cancer Center
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
Pleasant Hill : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
San Francisco : St Mary's Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
San Francisco : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
San Francisco : San Francisco Oncology Associates
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy
San Francisco : University of California, San Francisco
BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma
San Francisco : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
San Francisco : Northern California Melanoma Center/ St. Mary's Medical Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
San Francisco : Call for Information (Investigational Site 0008) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
San Francisco : UCSF Helen Diller Comprehensive Cancer Center
Trial of pIL-12 Electroporation Malignant Melanoma
Santa Monica : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Santa Monica : The Angeles Clinic
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Santa Monica :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Santa Monica : John Wayne Cancer Institute
Trial of pIL-12 Electroporation Malignant Melanoma
Santa Rosa : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Stanford : Stanford Cancer Center - Stanford University
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Temecula : Pacific Dermatology Institute
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Vallejo : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Colorado
Aurora : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Aurora :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Aurora : University of Colorado Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Aurora : Anschutz Cancer Pavilion
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Aurora :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
View More »
Denver : University of Colorado, Denver
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Denver : Rocky Mountain Cancer Centers
Safety Study of PLX108-01 in Patients With Solid Tumors
Connecticut
Hamden : New England Retina Associates
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
New Haven : Yale University School Of Medicine
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
District of Columbia
Washington : The Melanoma Center at the Washington Cancer Institute
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Washington : MedStar Clinical Research Ctr at Washington Hospital Center
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Florida
Fort Myers : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Jacksonville : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Jacksonville : Baptist Cancer Institute
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Jacksonville : Call for Information (Investigational Site 0003) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Lakeland : Lakeland Regional Cancer Center
Trial of pIL-12 Electroporation Malignant Melanoma
View More »
Miami Beach : Research Site
A Phase 1 Study to Evaluate MEDI4736
Miami Beach : Mount Sinai Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Miami Beach : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Miami Beach : MSMC Research Program Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Miami Beach : Mount Sinai Medical Center Comprehensive Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Miami Beach : Mount Sinai Medical Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Miami Beach : Call for Information (Investigational Site 0053) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Orlando : Md Anderson Cancer Center Orlando
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy
Orlando : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Orlando : Md Anderson Cancer Center Orlando
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Orlando : MD Anderson Cancer Center-Orlando
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Ormond Beach : Ameriderm Research
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Saint Petersburg : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
St. Petersburgh :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Tallahassee : Dermatology Associates of Tallahassee
Post-Approval Study of MelaFind
Tampa : Research Site
A Phase 1 Study to Evaluate MEDI4736
Tampa :
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma
Tampa : H. Lee Moffitt Cancer Center/University of South Florida Moffitt SC
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Tampa : H. Lee Moffitt Cancer Center/University of South Florida Moffitt 5
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Tampa :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study
Tampa : Moffitt Cancer Center
Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LC
Tampa : Call for Information (Investigational Site 0018) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Tampa : H. Lee Moffitt Cancer Center
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Tampa :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
Georgia
Atlanta : Winship Cancer Institute
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Augusta : Research Site
A Phase 1 Study to Evaluate MEDI4736
Illinois
Elgin : Sherman Health
ECOG E1609 Phase III Randomized Study of Adjuvant Ipilimumab Versus High-Dose Recombinant Interferon Alfa-2b in Patients With High-Risk Stage IIIB, IIIC, or IV Melanoma
View More »
Chicago : Rush University Medical Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Chicago : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Chicago : Rush University Medical Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Chicago : Rush Pres St Lukes Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Chicago : Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma
Chicago : University of Chicago
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Maywood : Loyola University Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Niles : Oncology Specialists, SC
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Niles : Oncology Specialists, SC (OSSC)
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Park Ridge : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Park Ridge : Oncology Specialists, SC
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Park Ridge :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Indiana
Goshen : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Goshen : Indiana University Health Goshen Center for Cancer Care
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Indianapolis : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Indianapolis : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Indianapolis : Indiana University Melvin and Bren Simon Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
View More »
Indianapolis : Indiana University - Simon Cancer Center
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Indianapolis : Indiana University Melvin And Bren Simon Cancer Center
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Indianapolis : Investigative Clinical Research of Indiana
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Iowa
Iowa City : University of Iowa Hospitals and Clinics Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Iowa City : University of Iowa Hospitals and Clinics
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Iowa City : University of Iowa Hospitals and Clinics
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Iowa City : University of Iowa Hospitals and Clinics
Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat
Kentucky
Lexington : Central Kentucky Research Associates
Melanoma Vaccine
View More »
Lexington : Central Baptist Hospital
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Lexington : Central Kentucky Research Associates
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Louisville : James Graham Brown Cancer Center
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Louisville : University of Louisville Hospital
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Louisiana
Baton Rouge : The Baton Rouge Clinic, AMC
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Maryland
Baltimore : Weinberg Cancer Institution at Franklin Square
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Bethesda :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Massachusetts
Boston : Massachusetts General Hospital Mass General 2
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Boston : Dana Farber Cancer Institute DFCI (4)
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Boston : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Boston : Massachusetts General Hospital Mass General 2 Updated
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Boston :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
View More »
Boston :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Boston : Dana-Farber Cancer Institute
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Boston : Dana-Farber Cancer Institute
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Boston : Beth Israel Deaconess Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Boston : Massachusetts Eye & Ear Infirmary
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
Boston : Dana Farber Cancer Institute DFCI - Brookline
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Boston : Massachusetts General Hospital Cancer Center
Safety Study of MGA271 in Refractory Cancer
Boston : Beth Israel Deaconess Medical Center
Safety Study of PLX108-01 in Patients With Solid Tumors
Boston : Dana Farber Cancer Institute
Safety Study of PLX108-01 in Patients With Solid Tumors
Boston : Massachusetts General Hospital
Safety Study of PLX108-01 in Patients With Solid Tumors
Boston : Massachusetts General Hospital Updated
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Boston : Dana-Farber Cancer Institute Updated
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Boston : Dana-Farber Cancer Institute Updated
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Boston : Call for Information (Investigational Site 0011) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Boston : Dana-Farber Cancer Institute Updated
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Boston : Massachusetts General Hospital Updated
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Boston : Beth Israel Deaconess Medical Center Updated
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Boston : Massachusetts General Hospital Updated
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Rockland, MA for US Recruiting Sites : Please contact the US Medical Information in
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Michigan
Detroit : Wayne State University/Karmanos Cancer Institute Wayne St
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Detroit : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Detroit :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Detroit : Karmanos Cancer Institute Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Detroit : Barbara Ann Karmanos Cancer Institute
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
View More »
Detroit : Henry Ford Medical Center
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Minnesota
Minneapolis : University of Minnesota Masonic Cancer Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Minneapolis : University of Minnesota Masonic Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Minneapolis : University of Minnesota Masonic Cancer Institute
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Rochester : Mayo Clinic
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Rochester :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
View More »
Rochester : Mayo Clinic Cancer Center, Mayo Clinic Rochester
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Rochester : Call for Information (Investigational Site 0002) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Missouri
Kansas City : Center for Pharmaceutical Research
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
St. Louis :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
St. Louis : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
St. Louis : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
St. Louis : Washington University in St. Louis
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma
View More »
St. Louis : Washington University in St. Louis
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
St. Louis : St. Louis Hospital
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
St. Louis : Washington University School of Medicine
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
St. Louis :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
St. Louis : Washington University in St. Louis Updated
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Nebraska
Lincoln : Southeast Nebraska Hematology & Oncology Consultants, Lincol
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Omaha : Midwest Cancer Center - Legacy
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Nevada
Las Vegas :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Las Vegas : Comprehensive Cancer Centers of Nevada
Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers
Las Vegas : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Las Vegas : Comprehensive Cancer Centers of Nevada
Safety Study of PLX108-01 in Patients With Solid Tumors
New Hampshire
Lebanon : Dartmouth-Hitchcock Medical Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Lebanon : Dartmouth Hitchcock Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Lebanon : Norris Cotton Cancer Center / Dartmouth-Hitchcock Medical Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
New Jersey
Hackensack : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Hackensack : John Theurer Cancer Center at Hackensack University Medical Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Hackensack : John Theurer Cancer Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Morristown : Atlantic Melanoma Center
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Morristown : Atlantic Melanoma Center
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
View More »
New Brunswick : Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
Effects of Monoclonal Antibody GC1008 in Blood Samples From Patients With Unresectable Locally Advanced or Metastatic Kidney Cancer or Malignant Melanoma Treated on Clinical Trial NCI-06-C-0200
New Brunswick : Cancer Center of NJ
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Randolph : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
New Mexico
Albuquerque : New Mexico Cancer Care Alliance
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
New York
Bronx : Saint Luke's-Roosevelt Hospital Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Bronx : Montefiore Medical Center
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
New York : Research Site
A Phase 1 Study to Evaluate MEDI4736
New York : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
New York : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
View More »
New York : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
New York :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
New York : Memorial Sloan Kettering Cancer Center
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
New York : Memorial Sloan Kettering Cancer Center
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
New York : New York University Langone Clinical Cancer Center
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
New York : Memorial Sloan Kettering Cancer Center
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
New York : Memorial Sloan-Kettering Cancer Center
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
New York : Memorial Sloan Kettering Cancer Center MSKCC 4
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
New York : Memorial Sloan-Kettering Cancer Center (MSKCC)
Safety Study of PLX108-01 in Patients With Solid Tumors
New York : Mount Sinai School of Medicine
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
New York : Call for Information (Investigational Site 0019) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
New York : New York University
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
New York :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
New York : Memorial Sloan Kettering Cancer Center Updated
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
New York : Melanoma and Sarcoma Service / Memorial Sloan Kettering Cancer Center
Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors
New York : Memorial Sloan-Kettering Cancer Center
Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation
NY : Mount Sinai School Of Medicine
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
North Carolina
Raleigh : Wake Research Associates
Melanoma Vaccine
View More »
Chapel Hill : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Chapel Hill : Lineberger Comprehensive Cancer Center, University of North Carolina
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Charlotte :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Charlotte : Levine Cancer Institute
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Charlotte : Blumenthal Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Durham : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Durham : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Durham : Duke University Medical Center
Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion
Durham : Duke University Hospital
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Durham : Duke University Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Durham : Call for Information (Investigational Site 0036) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Raleigh : Wake Research Associates
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Winston Salem : Wake Forest University Baptist Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Winston-salem : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Winston-Salem : Wake Forest University School of Medicine, Comprehensive Cancer Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Ohio
Cincinnati : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Cleveland : Case Comprehensive Cancer Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Cleveland : University Hospitals Of Cleveland
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Cleveland : University Hospitals Siedman Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Columbus : The Ohio State University Comprehensive Cancer Center
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Oregon
Portland : Oregon Health & Science University OHSU 2
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Portland : Providence Cancer Center
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.
Portland : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Portland : Providence Cancer Center Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Portland : Providence Portland Medical Center
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
View More »
Portland : Providence Portland Medical Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Portland : Portland Providence Medical Center
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Portland : Kaiser Permanente Northwest
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Portland : Oregon Health and Science University
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Pennsylvania
Bethlehem : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Bethlehem : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Bethlehem : Saint Luke's Hospital and Health Network
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Bethlehem : Call for Information (Investigational Site 0001) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Easton : St. Luke's Hospital, Anderson Campus Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
View More »
Philadelphia :
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma
Philadelphia : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Philadelphia : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Philadelphia : Thomas Jefferson University
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center
Safety Study of MGA271 in Refractory Cancer
Philadelphia : Fox Chase Cancer Center
Safety Study of PLX108-01 in Patients With Solid Tumors
Philadelphia : Pennsylvania Oncology Hematology Associates
Safety Study of PLX108-01 in Patients With Solid Tumors
Philadelphia : University of Pennsylvania
Safety Study of PLX108-01 in Patients With Solid Tumors
Philadelphia : Kimmel Cancer Center at Thomas Jefferson Univ.
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Philadelphia : Call for Information (Investigational Site 0016) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Philadelphia : Fox Chase Cancer Center
Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
Philadelphia : University of Pennsylvania
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Pittsburgh : UPMC Cancer Centers Updated
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Pittsburgh : Hillman Cancer Center
Melanoma Molecular Profiling Analysis
Pittsburgh : Updated
Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma
Pittsburgh : UPMC Hillman Cancer Center
Pilot Study of IFN α2b for Melanoma Patients
Pittsburgh : Hillman Cancer Research Pavilion, Div. of Medical Oncology
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Pittsburgh : University of Pittsburgh
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Pittsburgh : Call for Information (Investigational Site 0013) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Pittsburgh : University of Pittsburgh Cancer Institute
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Pittsburgh :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
South Carolina
Greenville : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Tennessee
Memphis :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Memphis : St. Jude Children'S Research Hospital
Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma
Nashville : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Nashville : Sarah Cannon Research Institute
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Nashville :
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
View More »
Nashville : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Nashville : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Nashville : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Nashville : Vanderbilt-Ingram Cancer Ctr
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Nashville : Sarah Cannon Research Institute
Safety Study of MGA271 in Refractory Cancer
Nashville : Vanderbilt-Ingram Medical Center
Safety Study of PLX108-01 in Patients With Solid Tumors
Nashville : Call for Information (Investigational Site 0033) Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Nashville : Vanderbilt-Ingram Cancer Center
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Nashville :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Nashville : Vanderbilt University Updated
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
Nashville : Sarah Cannon Research Institute Updated
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Texas
Dallas : Research Across America
Do You Have Melanoma?
View More »
Amarillo : Don and Sybil Harrington Cancer Center
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Dallas : Mary Crowley Cancer Research Centers - Medical City
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Dallas : Mary Crowley Cancer Research Centers
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Dallas :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Dallas : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Dallas : Mary Crowley Cancer Research Centers
Phase II FANG in Advanced Melanoma
Dallas : Mary Crowley Cancer Research Center
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Dallas : Texas Oncology, PA (North)
Safety Study of PLX108-01 in Patients With Solid Tumors
Dallas : Dallas Surgical Group
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Dallas : Research Across America
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Dallas : Mary Crowley Cancer Research Center
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Dallas :
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Dallas : Mary Crowley Cancer Research Center
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Houston : UT MD Anderson Cancer Center
A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma
Houston : MD Anderson Cancer Center/University of Texas MD Anderson 2
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Houston :
A Study of The Safety and Pharmacology of MPDL3280A Administered in Combination With Vemurafenib (Zelboraf®) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma
Houston :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Houston : UT MD Andreson Cancer Center
GSK2118436 and GSK1120212
Houston : UT MD Anderson Cancer Center
High-dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
Houston : UT MD Anderson Cancer Center
Ipilimumab for Uveal Melanoma
Houston : The University of Texas MD Anderson Cancer Center
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization
Houston : MD Anderson Cancer Center
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Houston : University of Texas M.D. Anderson Cancer Center
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma
Houston : University of Texas MD Anderson Cancer Center
Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma
Houston : Call for Information (Investigational Site 0012) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Houston : UT MD Anderson Cancer Center
Study of Weekly LOC-paclitaxel Injection for Melanoma
Houston : The University of Texas MD Anderson Cancer Center
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
Houston : UT MD Anderson Cancer Center
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma
San Antonio : Call for Information (Investigational Site 0001) Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
San Antonio : The START Center
Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma
San Antonio : Cancer Therapy & Research Center at UTHSCSA
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
San Antonio : Cancer Therapy and Research Center Updated
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors
Utah
Murray : Intermountain Medical Center
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Salt Lake : Huntsman Cancer Institute
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Salt Lake City : Huntsman Cancer Institute
A Study of Intratumoral CAVATAK in Patients With Stage IIIc and Stage IV Malignant Melanoma
Salt Lake City : University of Utah / Huntsman Cancer Institute Huntsman Updated
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Salt Lake City : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
View More »
Salt Lake City : Huntsman Cancer Institute
Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks
Salt Lake City : The Huntsman Cancer Institute, University of Utah
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Vermont
Burlington : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Burlington : Fletcher Allen Health Care, Inc.
Safety Study of Adenovirus Vector Engineered to Express hIL-12 (Human Interleukin 12) in Combination With Activator Ligand to Treat Melanoma
Virginia
Charlottesville : University of Virginia
A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients
Charlottesville : University of Virginia Health System
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
Charlottesville : University of Virginia Hospital
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Charlottesville : University of Virginia
Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI
Norfolk : Virginia Oncology Associates
Safety Study of PLX108-01 in Patients With Solid Tumors
View More »
Norfolk : Clinical Research Associates of Tidewater
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Washington
Seattle :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Seattle : Seattle Cancer Care Alliance
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma
Seattle : Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Trial of pIL-12 Electroporation Malignant Melanoma
Spokane : Evergreen Hematology & Oncology
Safety Study of PLX108-01 in Patients With Solid Tumors
West Virginia
Morgantown : West Virginia University - Clinical Trials Research Unit
ECOG 1609 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
Argentina
Buenos Aires : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Buenos Aires : Instituto Médico Alexander Fleming
Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients
Caba : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Capital Federal : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Rosario : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Australia
Adelaide : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Box Hill : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
East Melbourne :
A Study of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Frankston : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Gateshead : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
View More »
Greenslopes : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Greenslopes : GSK Investigational Site
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.
Greenslopes : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Heidelberg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Herston : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Herston :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Herston : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Hobart : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Kurralta Park : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Lismore : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Melbourne : Novartis Investigative Site
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Melbourne : Updated
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Melbourne :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Melbourne : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Nedlands : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Nedlands : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
North Sydney : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
North Sydney : GSK Investigational Site
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.
North Sydney : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
North Sydney : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Parkville : Novartis Investigative Site Updated
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
South Brisbane : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
South Granville : Merck Sharp & Dohme/Australia Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
St Leonards : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Tiwi : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Wentworthville :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Westmead : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Westmead :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Westmead : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Woodville : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Woolloongabba : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Woolloongabba : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Austria
Innsbruck : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Linz : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Salzburg : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Salzburg : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Vienna : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
View More »
Wels : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Wien : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Belgium
Antwerp : Universitair Ziekenhuis Antwerpen
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Brasschaat : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Brussels : Jules Bordet Institute
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Brussels : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Brussels : Cliniques universitaires Saint-Luc, Centre du Cancer
Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients
View More »
Bruxelles : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Bruxelles : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Bruxelles : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Gent : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Hasselt : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Jette : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Jette : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Kortrijk : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Kortrijk : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Leuven : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Leuven : Novartis Investigative Site Updated
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Leuven : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Wilrijk : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Wilrijk : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Bosnia and Herzegovina
Banja Luka : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Brazil
Belo Horizonte : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Porto Alegre : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Rio de Janeiro : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Rio de Janeiro : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Salvador : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
View More »
Sao Paulo : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
São Paulo : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Bulgaria
Plovdiv : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Sofia : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Canada
Calgary : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Edmonton : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Edmonton : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Halifax : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Hamilton : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
View More »
Kingston : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Kirkland : Merck Frosst Canada Ltd. Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
London : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Montreal : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Montreal : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Montreal : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Montreal : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Oshawa : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Ottawa : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Quebec : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Quebec : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Toronto : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Toronto : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Toronto : Novartis Investigative Site Updated
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Toronto : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Toronto :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Toronto : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Vancouver : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Vancouver : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Winnipeg : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Winnipeg : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Colombia
Medellin : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Croatia
Zagreb : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Czech Republic
Brno : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Hradec Kralove : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Olomouc : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Praha : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Praha 10 : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
View More »
Praha 2 : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Denmark
Århus C : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Herlev : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Odense : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Ecuador
Guayaquil : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Portoviejo : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Finland
Helsinki : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Helsinki : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Helsinki : Local Institution
Study of BMS-936558 vs. Dacarbazine in Untreated, Unresectable or Metastatic Melanoma
Tampere : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
France
Avignon Cedex 2 : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Bayonne : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Bordeaux : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Bordeaux :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Bordeaux : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
View More »
Bordeaux : Hôpital Saint-André
DNA Repair Inhibitor & Irradiation on Melanoma
Boulogne Billancourt :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Boulogne sur Mer : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Boulogne-Billancourt : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Boulogne-Billancourt : Hôpital Ambroise Paré
DNA Repair Inhibitor & Irradiation on Melanoma
Brest Cedex : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Colmar :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret Updated
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Dijon : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Grenoble : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Lille :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Lille :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Lille : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Lille : Centre Oscar Lambret
DNA Repair Inhibitor & Irradiation on Melanoma
Lille : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Lyon :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Lyon Cedex 08 : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Marseille : Hôpital Sainte Marguerite
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Dacarbazine in the Treatment of Patients With Non-Resectable or Metastatic Stage 3 or Stage 4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of C-Kit
Marseille :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Marseille : Hôpital de la Timone
DNA Repair Inhibitor & Irradiation on Melanoma
Marseille cedex 5 : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Marseille Cedex 5 : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Montauban : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Montivilliers : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Montpellier :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Montpellier : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Montpellier cedex 5 : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Nantes :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Nantes : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Nantes : Hôpital hôtel-Dieu
DNA Repair Inhibitor & Irradiation on Melanoma
Nantes : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Nantes : Centre Hospitalier Universitaire de Nantes
Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face
Nice :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Nice : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Paris : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Paris :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Paris :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Paris : Hôpital Saint-Louis
DNA Repair Inhibitor & Irradiation on Melanoma
Paris : Institut Curie
DNA Repair Inhibitor & Irradiation on Melanoma
Paris : Groupe Hospitalier Cochin - Hôtel Dieu-Broca
DNA Repair Inhibitor & Irradiation on Melanoma
Paris : Novartis Investigative Site
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Paris Cedex 10 : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Paris Cedex 10 : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Paris cedex 18 : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Pessac :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Quimper : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Reims Cedex : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Rennes : Centre Eugène Marquis
cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project
Rennes : Rennes University Hospital
cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project
Rennes Cedex : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Rouen :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Toulouse Cedex : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Toulouse Cedex 3 : Novartis Investigative Site
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Toulouse Cedex 3 : Novartis Investigative Site Updated
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Vandoeuvre les Nancy : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Vandoeuvre Les Nancy :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Villejuif :
Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples
Villejuif Cedex : Novartis Investigative Site
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Villejuif cedex : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Germany
Aachen : Dept of Dermatology, University of Aachen
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Augsburg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Augsburg : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Berlin : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Berlin : Dept of Dermatology, University of Berlin Charite
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
View More »
Bochum : Dept of Dermatology, University of Bochum
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Bonn : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Bonn : Medizinisches Zentrum Bonn Friedensplatz
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Buxtehude : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Buxtehude : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Dresden : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Erfurt : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Erfurt : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Erlangen : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Essen : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Essen : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Essen : GSK Investigational Site
A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.
Essen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Essen : Dept of Dermatology, University of Essen
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Essen : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Essen : Medizinische Fakultät der Universität Duisburg-Essen
RBL001/RBL002 Phase I Clinical Trial
Frankfurt :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Frankfurt / Main : Dept of Dermatology, University of Frankfurt
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Frankfurt/Oder : Dermatology, Klinikum Frankfurt/Oder
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Freiburg : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Freiburg : University Medical Center Freiburg, Department of Dermatology
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
Gera : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Gera : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Gera : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Hannover : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Hannover : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Hannover : Dept of Dermatology, University of Hannover
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Hannover : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Hannover : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Heidelberg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Heidelberg : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Heidelberg : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Heilbronn : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Homburg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Homburg/Saar : Dept of Dermatology, Saarland University
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Jena : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Jena : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Jena : Dept of Dermatology, University of Jena
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Kiel : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Kiel : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Kiel : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Kiel :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Kiel :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Kiel : Dept of Dermatology, University of Schleswig-Holstein Campus Kiel
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Kiel : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Kiel : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Koeln : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Koeln : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Koeln : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Köln : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Köln : University Medical Center Collogne, Department of Dermatology
Quality of Life and Psychological Well-being in Patients With Malignant Melanoma
Leipzig : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Leipzig : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Lübeck : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Ludwigshafen : Dermatology, Klinikum Ludwishafen
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Ludwigshafen : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Luebeck : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Luebeck : Dept of Dermatology, University of Schleswig-Holstein Campus Luebeck
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Luebeck : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Magdeburg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Magdeburg : Dept of Dermatology, Univeristy of Magdeburg
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Mainz : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Mainz :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Mainz : Dept of Dermatology, University of Mainz
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Mainz : Universtitätsmedizin der Johannes-Gutenberg Universtität
RBL001/RBL002 Phase I Clinical Trial
Manheim : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Mannheim : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Mannheim : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Mannheim :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Mannheim : Dept of Dermatology, University of Mannheim
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Mannheim : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Mannheim : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Marburg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Marburg : Dept of Dermatology, University of Marburg
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Muenchen : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Muenchen : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Muenchen : Dept of Dermatology, University of Muenchen
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Muenchen : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Muenster : Dept of Dermatology, University of Muenster
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Muenster : Dept of Medical Oncology, Fachklinik Hornheide
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Münster :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Nuernberg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Quedlinburg : Dermatology, Klinikum Dorothea Christiane Erxleben
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Regensburg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Regensburg : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Regensburg : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Tübingen : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Tübingen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Tuebingen : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Tuebingen :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Tuebingen : Dept of Dermatology, University of Tuebingen
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Tuebingen : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Tuebingen : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Ulm : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Wiesbaden : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Wuerzburg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Wuerzburg : Dept of Dermatology, University of Wuerzburg
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
Wuerzburg : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Greece
Athens : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Athens : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Heraklion : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
N. Faliro : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Thessaloniki : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Hungary
Debrecen : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Szeged : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
India
Hyderabad : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Lucknow : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Mumbai : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Nashik : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
New Delhi : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Trivandrum : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Vellore : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Ireland
Co.Cork : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Cork : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Cork : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Dublin : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Dublin : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
View More »
Dublin 7 : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Galway : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Galway : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Limerick : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Tullamore : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Waterford : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Israel
Beer Sheva : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Haifa : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Hod Hasharon : Merck Sharp & Dohme Co. Ltd. Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Jerusalem : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Jerusalem : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
View More »
Jerusalem : Oncology institute, Shaare Zedek Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Ramat Gan : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Tel Hashomer : Ella Institute, Oncology institute, Sheba Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel Hashomer : Oncology Institute, Sheba Medical Center
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
Tel-hashomer :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Italy
Bari : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Bergamo : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Bergamo : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Bergamo : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Bergamo : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
View More »
Candiolo (TO) : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Firenze : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Genova : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Genova : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Genova : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Genova :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Genova : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Meldola : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Milano : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Milano : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Milano :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Milano :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Milano : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Milano : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Milano : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Napoli : Updated
A Phase 3 Study Comparing GDC-0973, a MEK Inhibitor, in Combination With Vemurafenib vs Vemurafenib Alone in Patients With Metastatic Melanoma
Napoli : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Napoli : Novartis Investigative Site Updated
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Napoli : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Napoli : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Napoli : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Padova : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Padova : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Padova : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Padova : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Pisa : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Pisa : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Roma : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Roma : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Roma :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Siena : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Siena : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Siena :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Siena : GSK Investigational Site
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
Udine : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Japan
Chuo-ku : Local Institution
Phase 2 Study of Ipilimumab Plus DTIC in Japanese Advanced Melanoma Patients
Tokyo : MSD K.K.
A Study of Pegylated Interferon Alfa-2b as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (P08556)
Korea, Republic of
Seoul : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Lithuania
Klaipeda : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Vilnius : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Macedonia, The Former Yugoslav Republic of
Skopje : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Netherlands
Amsterdam : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Amsterdam :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Amsterdam : Antoni van Leeuwenhoek Ziekenhuis
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Amsterdam : Vrije Universiteit medisch centrum (Vumc)
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Amsterdam : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
View More »
Amsterdam : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Blaricum : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Breda : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Groningen : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Groningen :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Groningen : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Haarlem : Merck Sharp & Dohme BV Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Leiden : Leids Universitair Medisch Centrum (LUMC)
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Leiden : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Leiden : Novartis Investigative Site
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Maastricht : Novartis Investigative Site
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Maastricht : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Maastricht : Maastricht Universitair Medisch Centrum
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Maastricht : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Rotterdam : Novartis Investigative Site
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Rotterdam : Erasmus MC
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
Rotterdam : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Rotterdam : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Zwolle : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
New Zealand
Christchurch : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Newtown, Wellington : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Norway
Bergen : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Drammen : MSD (Norge) AS Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Kristiansand : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Oslo : Novartis Investigative Site
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Oslo : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Oslo : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Peru
Arequipa : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Poland
Gdansk : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Konin : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Poznan : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Poznan : WCO (Great Poland Cancer Centre)
Safety and Pharmacodynamic Study of a New Formulation, AGI - 101H Vaccine in the Treatment of Advanced Melanoma
Warszawa : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Romania
Timisoara : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Russian Federation
Kazan : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Moscow : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
St. Petersburg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Stavropol : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
South Africa
Bloemfontein : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Cape Town : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Johannesburg : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Pretoria : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Spain
Barcelona : Novartis Investigative Site
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Barcelona : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Barcelona : Novartis Investigative Site Updated
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Barcelona : Novartis Investigative Site
A Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands
Barcelona :
A Study of RO5212054 (PLX3603) in Patients With BRAF V600-mutated Advanced Solid Tumours
View More »
Barcelona :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Barcelona : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Cordoba : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Granada : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Hospitalet de Llobregat, Barcelona : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
La Coruna : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
La Laguna (tenerife) : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Las Palmas De Gran Canaria : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Leon : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Madrid : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Madrid : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Madrid :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Madrid : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Madrid : Merck Sharp and Dohme de Espana S.A. Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Malaga : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Palma de Mallorca : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Pamplona : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Pamplona :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Pamplona : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Pamplona : Local Institution
Phase 1 Biomarker Study of Anti-PD-1 in Advanced Melanoma
Valencia : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Valencia : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Valencia : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Zaragoza : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Sweden
Goteborg : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Göteborg : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Jönköping : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Linköping : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Lund : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
View More »
Lund : Lunds Universitetssjukhus
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Malmö : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Sollentuna : MSD Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Stockholm : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Stockholm : Södersjukhuset
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Stockholm : Karolinska Sjukhuset
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Umeå : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Umeå : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Umeå : Norrlands Universitetssjukhus
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
Uppsala : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Uppsala : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Switzerland
Baden : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Genève : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Glattbrugg : MSD Merck Sharp & Dohme AG Updated
Study of MK-3475 Versus Chemotherapy in Participants With Advanced Melanoma (P08719/MK-3475-002)
Lausanne : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Lugano : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
View More »
Zuerich : Novartis Investigative Site
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
Zürich : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Zürich : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Zürich : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Thailand
Bangkok : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Songkla : Novartis Investigative Site
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
Turkey
Adana : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Adana : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Ankara : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Ankara : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Antalya : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
View More »
Bakesir : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Bornova, Zmr : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Bursa : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Diyarbakir : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Edirne : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Erzurum : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Gaziantep : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Gaziantep : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Isparta : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Istanbul : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Istanbul : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Izmir : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Izmir : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Kayseri : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Konya : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Malatya : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Shhiye, Ankara : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Shhiye, Ankara : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Tokat : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Trabzon : Updated
A Non-Interventional Study of the Occurrence Rate of Colon, Breast and Gastric Cancer and Malignant Melanoma in Turkey and Diagnosis and Treatment Characteristics
Ukraine
Dnipropetrovsk : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Donetsk : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Khmelnytskyi : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Kyiv : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Lviv : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
View More »
Sumy : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
United Kingdom
Bebington : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Birmingham : Queen Elizabeth Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Cambridge : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Cambridge : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Cambridge : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
View More »
Cambridge : Cambridge University Hospitals NHS Foundation Trust
HYPAZ: Hypertension Induced by Pazopanib
Cambridge : Addenbrooke's Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Chelmsford : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Edgbaston, Birmingham : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Edinburgh : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Glasgow : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Glasgow : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Glasgow : The Beatson Institute
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Leeds : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Leeds : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Leeds : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Leeds : St James' Institute of Oncology
Study of a DNA Immunotherapy to Treat Melanoma
Leeds : St James Hospital
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Leicester : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
London : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
London : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
London : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
London : King's College London Guy's Hospital Campus
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
London : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
London : Novartis Investigative Site
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Manchester : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Manchester : Christie Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Newcastle upon Tyne : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Newcastle Upon Tyne : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Newcastle Upon Tyne :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Newcastle Upon Tyne and Wear : Newcastle Upon Tyne NHS Foundation Trust
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Newcastle-upon-Tyne : Northern Centre for Cancer Care, Freeman Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Northwood : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Northwood : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Northwood :
A Study of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases
Nottingham : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Nottingham : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Nottingham : Department of Clinical Oncology, City Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Oxford : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Oxford : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Oxford : Updated
A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma
Oxford : NIHR Biomedical Research Centre
Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Preston : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Southampton : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Southampton : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Southampton : GSK Investigational Site
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Southampton : Department of Medical Oncology, Southampton General Hospital
Study of a DNA Immunotherapy to Treat Melanoma
Sutton : GSK Investigational Site
A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma
Sutton : Novartis Investigative Site Updated
A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
Sutton :
A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Swansea : Updated
A Study of RO5185426 in Patients With Metastatic Melanoma
Swansea : GSK Investigational Site
Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma
Truro, Cornwall : Local Institution
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
Wirral : Clatterbridge Centre for Oncology NHS Foundation Trust
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
